MA45843A - Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) - Google Patents

Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Info

Publication number
MA45843A
MA45843A MA045843A MA45843A MA45843A MA 45843 A MA45843 A MA 45843A MA 045843 A MA045843 A MA 045843A MA 45843 A MA45843 A MA 45843A MA 45843 A MA45843 A MA 45843A
Authority
MA
Morocco
Prior art keywords
ghrelin
goat
acyl transferase
transferase inhibitors
derivatives used
Prior art date
Application number
MA045843A
Other languages
English (en)
Other versions
MA45843B1 (fr
Inventor
Cédrickx Godbout
Thomas Trieselmann
Viktor Vintonyak
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA45843A publication Critical patent/MA45843A/fr
Publication of MA45843B1 publication Critical patent/MA45843B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des composés de formule générale (i) dans lesquels les groupes r1, r2 et n sont tels que définis dans la revendication 1, qui ont des propriétés pharmacologiques valorisables, en particulier, qui se lient au ghréline o-acyl transférase (chèvre) et modulent son activité. Ces composés conviennent pour traiter et prévenir des maladies pouvant être influencées par ce récepteur, telles que des maladies métaboliques, en particulier l'obésité
MA45843A 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre) MA45843B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16183047 2016-08-05
PCT/EP2017/069274 WO2018024653A1 (fr) 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Publications (2)

Publication Number Publication Date
MA45843A true MA45843A (fr) 2019-06-12
MA45843B1 MA45843B1 (fr) 2021-06-30

Family

ID=56609762

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45843A MA45843B1 (fr) 2016-08-05 2017-07-31 Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)

Country Status (32)

Country Link
US (3) US9994591B2 (fr)
EP (1) EP3494120B1 (fr)
JP (1) JP6651054B2 (fr)
KR (1) KR102496075B1 (fr)
CN (1) CN109843891B (fr)
AR (1) AR109296A1 (fr)
AU (1) AU2017307033B2 (fr)
CA (1) CA3033058A1 (fr)
CL (1) CL2019000274A1 (fr)
CO (1) CO2019000601A2 (fr)
CY (1) CY1124381T1 (fr)
DK (1) DK3494120T3 (fr)
EA (1) EA037277B1 (fr)
ES (1) ES2874587T3 (fr)
HR (1) HRP20210908T1 (fr)
HU (1) HUE054928T2 (fr)
IL (1) IL264506B (fr)
LT (1) LT3494120T (fr)
MA (1) MA45843B1 (fr)
MX (1) MX2019001427A (fr)
MY (1) MY197064A (fr)
PE (1) PE20190414A1 (fr)
PH (1) PH12019500254A1 (fr)
PL (1) PL3494120T3 (fr)
PT (1) PT3494120T (fr)
RS (1) RS61937B1 (fr)
SA (1) SA519401039B1 (fr)
SG (1) SG11201811804QA (fr)
SI (1) SI3494120T1 (fr)
TW (1) TWI749042B (fr)
UA (1) UA124267C2 (fr)
WO (1) WO2018024653A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019149658A1 (fr) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat)
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746450B1 (fr) * 2018-02-02 2022-03-16 Boehringer Ingelheim International GmbH Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
CR20200332A (es) * 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
JP2023526351A (ja) 2020-05-22 2023-06-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルキル7-アミノ-5-メチル-[1,2,5]オキサジアゾロ[3,4-b]ピリジンカルボキシレートの製造方法
EP4153600A1 (fr) 2020-05-22 2023-03-29 Boehringer Ingelheim International GmbH Procédé continu de fabrication de 7-amino-5-méthyl-[1,2,5] oxadiazolo [3,4-b] pyridine-carboxylate d'alkyle
CN112014340A (zh) * 2020-09-01 2020-12-01 广西玮美生物科技有限公司 非人灵长类动物胃饥饿素的检测方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2241496B1 (es) 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
JP2010512366A (ja) 2006-12-11 2010-04-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Mch拮抗活性を有する新規ピリダジン誘導体及びこれらの化合物を含む薬物
EP2111414B1 (fr) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Co-agonistes des récepteurs du glucagon/glp-1
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
BRPI0823379A2 (pt) 2008-12-15 2015-07-14 Zealand Pharma As Análogos de glucagon
MX2011006314A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
AU2008365555B2 (en) 2008-12-15 2016-01-14 Zealand Pharma A/S Glucagon analogues
EA020596B1 (ru) 2008-12-15 2014-12-30 Зилэнд Фарма А/С Аналоги глюкагона
JP6054742B2 (ja) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
AU2011269430A1 (en) 2010-06-24 2013-01-10 Zealand Pharma A/S Glucagon analogues
CN104144696A (zh) 2011-12-23 2014-11-12 西兰制药公司 胰高血糖素类似物
WO2013125732A1 (fr) * 2012-02-24 2013-08-29 Takeda Pharmaceutical Company Limited Composé à noyau aromatique
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA118034C2 (uk) 2013-11-14 2018-11-12 Елі Ліллі Енд Компані Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази
US20170275249A1 (en) * 2014-09-17 2017-09-28 The Regents Of The University Of California Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase
AR104672A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
AR104673A1 (es) 2015-04-15 2017-08-09 Lilly Co Eli Inhibidores de grelina o-aciltransferasa
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
EP3746450B1 (fr) 2018-02-02 2022-03-16 Boehringer Ingelheim International GmbH Dérivés d'oxadiazolopyridine à substitution hétérocyclyle utilisés en tant qu'inhibiteurs de la ghréline o-acyltransférase (goat)
WO2019149658A1 (fr) * 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat)
CR20200332A (es) 2018-02-02 2020-09-03 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustitidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)

Also Published As

Publication number Publication date
TW201817735A (zh) 2018-05-16
CA3033058A1 (fr) 2018-02-08
CO2019000601A2 (es) 2019-02-08
PT3494120T (pt) 2021-05-26
US20180251476A1 (en) 2018-09-06
SG11201811804QA (en) 2019-01-30
WO2018024653A1 (fr) 2018-02-08
RS61937B1 (sr) 2021-07-30
US9994591B2 (en) 2018-06-12
HUE054928T2 (hu) 2021-10-28
EP3494120A1 (fr) 2019-06-12
JP6651054B2 (ja) 2020-02-19
US20180037594A1 (en) 2018-02-08
SA519401039B1 (ar) 2021-11-25
US10308667B2 (en) 2019-06-04
EP3494120B1 (fr) 2021-03-17
EA201990418A1 (ru) 2019-08-30
CY1124381T1 (el) 2022-07-22
KR20190035859A (ko) 2019-04-03
IL264506A (en) 2019-02-28
UA124267C2 (uk) 2021-08-18
PH12019500254A1 (en) 2019-06-03
CN109843891B (zh) 2021-11-23
CN109843891A (zh) 2019-06-04
PL3494120T3 (pl) 2021-09-20
MA45843B1 (fr) 2021-06-30
EA037277B1 (ru) 2021-03-03
CL2019000274A1 (es) 2019-05-03
SI3494120T1 (sl) 2021-08-31
TWI749042B (zh) 2021-12-11
USRE49446E1 (en) 2023-03-07
ES2874587T3 (es) 2021-11-05
KR102496075B1 (ko) 2023-02-06
MX2019001427A (es) 2019-06-10
NZ749290A (en) 2021-08-27
PE20190414A1 (es) 2019-03-19
AU2017307033A1 (en) 2019-01-17
MY197064A (en) 2023-05-24
DK3494120T3 (da) 2021-05-31
HRP20210908T1 (hr) 2021-09-03
IL264506B (en) 2021-03-25
AR109296A1 (es) 2018-11-14
JP2019524786A (ja) 2019-09-05
LT3494120T (lt) 2021-05-25
AU2017307033B2 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
MA45843B1 (fr) Dérivés d'oxadiazolopyridine utilisés comme inhibiteurs de la ghréline o-acyl transférase (chèvre)
EA200801934A1 (ru) 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2
EA201000332A1 (ru) 1,3-двузамещенные 4-фенил-1н-пиридин-2-оны
MA20150065A1 (fr) Nouveaux dérivés d'acide indanyloxydihydrobenzofurannylacétique et leur utilisation comme agonistes du récepteur gpr40
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
MA45153B1 (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA38170A1 (fr) Nouveaux acides indanyloxydihydrobenzofuranylacétiques
EA200700617A1 (ru) Новые пиридиновые производные и их применение в качестве позитивных аллостерических модуляторов mglur2-рецепторов
MX2020007994A (es) Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA200901159A1 (ru) Производные 3-циано-4-(4-фенилпиперидин-1-ил)пиридин-2-она
MX2011003691A (es) Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico.
MA40993B1 (fr) Dérivés de 4-oxo-3,4-dihydro-1,2,3-benzotriazine comme modulateurs gpr139
EA200901162A1 (ru) Производные 1,4-дизамещённого 3-цианопиридона и их применение в качестве положительных модуляторов рецептора mglur2
EA200901160A1 (ru) Производные 3-циано-4-(4-тетрагидропиранфенил)пиридин-2-она
MA31623B1 (fr) Nouveaux herbicides
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MX2020008116A (es) Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat).
MA50398B1 (fr) Dérivés d'imidazole condensés, substitués par des groupes hydroxy tertiaires, utilisés comme inhibiteurs de pi3k-gamma
CR20200355A (es) Compuestos para el tratamiento de trastornos dependientes de cinasas
MX2020013899A (es) Derivados de pirazol como inhibidores de malt1.
EA202190464A1 (ru) Замещенные бензимидазолы в качестве ингибиторов pad4
EA201190086A1 (ru) Сочлененные производные имидазола в качестве антагониста trpv3